Voyager Acquisition Corp (VRXAW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

$2.45M

MomentumView details →

1D Return

+21.12%

YTD Return

—

RSI (14)

49.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

$2.45M

RSI (14)

49.7

MomentumView details →

1D Return

+21.12%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

VERAXA Biotech announced a collaboration with Ardigen to support its BiTAC pipeline of T cell engagers and antibody drug conjugates.54d ago

Xlife Sciences AG disclosed a 16.3% stake in Veraxa Biotech Holding AG via a 13D/G filing.82d ago

Similar companies

CASI Pharmaceuticals, Inc.CASI BioXcel Therapeutics, Inc.BTAI Propanc Biopharma, Inc.PPCB Clearside Biomedical, Inc.CLSD Purple Biotech Ltd.PPBT Genprex, Inc.GNPX Find similar companies →

Latest newsMore news →

VERAXA Biotech announced a collaboration with Ardigen to support its BiTAC pipeline of T cell engagers and antibody drug conjugates.54d ago Xlife Sciences AG disclosed a 16.3% stake in Veraxa Biotech Holding AG via a 13D/G filing.82d ago VERAXA Biotech completed a business combination with Voyager Acquisition Corp. and will begin trading on NASDAQ under ticker VRXA on June 11, 2026.86d ago